Clinical Trial Search

Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters

Primary: Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis — 6.0; 3.2…

Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants

Primary: Median Values of ERG Scotopic Parameters at 12-month — 201; 210; 508; 92 microvolts — p=<0.001

Primary: Number of Participants Experiencing a Treatment Response by Week 16 — 4; 2 Participants

Primary: Number of Participants With Systemic Toxicities, Adverse Events, or Infections — 6 Participants

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants

Primary: Change in Neurological Disability - Expanded Disability Scale Score — 4.0; 6.5; 6.5; 4.0 EDSS unit score

Primary: Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. — 12.2 Change in ETDRS Letters — p=0.0015

Primary: Occurence Rate of Uveitis Attacks in Participants Before Anti-TNF/GLM Treatment and After the Start of GLM Treatment — 0.08; 0.08 Ratio — p=1.0000

Primary: The Primary Outcome is the Time to Recurrence of Uveitis in Participants of Each Treatment Group, During or After Tapering of Oral Prednisone to a Dose of 7.5 mg/Day, or…

Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events

Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003

Primary: Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography — 3; 1; 1 Participants

Primary: Change in Excess Central Macular Thickening in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline — -38.60 µm

Primary: The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5 — 28; 44; 27 Participants

Primary: Corticosteroid-sparing Treatment Success Within the First 6 Months After Randomization — 0.69; 0.54 Cumulative proportion of participants — p=0.029

Primary: Time to Treatment Failure on or After Week 6 — 3.0; 5.6; 3.0; 4.8 months — p=<0.001

Primary: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks — 45; 10 Participants — p=<0.001

Primary: Time to Treatment Failure on or After Week 2 — 8.3; NA; 5.6; NA months — p=0.004

Primary: Adverse Events — 27; 1 Participants

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died — 0; 0; 1; 1 participants

Primary: Number of Responders at Day 15 — 14; 9 Participants

Primary: Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival…

Primary: Adverse Events — 0; 0; 0 Participants

Primary: Number of Participants Achieving Treatment Success — 24; 15 participants — p=0.09

Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months

Primary: Number of Participants With Response Rate for the Individual Response Criteria - in the Study Eye — 3; 3; 0; 1 Participants

Primary: Number of Participants With Adverse Events — 398; 101 participants

Primary: Number of Participants Achieving Treatment Success at 6 Months (Phase I, 0-6 Months) — 64; 56 Participants